OncoMatch/Clinical Trials/NCT06916767
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
Is NCT06916767 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including BAFF CAR-T and Obinutuzumab for relapsed cll.
Treatment: BAFF CAR-T · Obinutuzumab · Cyclophosphamide · Fludarabine — CAR-T cell treatment of refractory lymphoma has shown success, particularly with CD-19 targeted CAR-T cells, however, many participants are refractory or relapse after response. Responses are more limited in CLL/SLL, possibly secondary to the suppressive effect of circulating B cells on T cell function. BAFF receptor is a target that has been explored in CLL. Preclinical data indicates that CAR- T cells expressing B-cell activating factor (BAFF) can be another effective strategy to treat refractory CLL. This study aims to explore the efficacy of LMY-920 a BAFF-ligand CAR T cells with depletion of B cells with Obinutuzumab prior to apheresis.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: BTK inhibitor
Relapsed after 2 or more lines of therapy, including a BTK inhibitor
Must have received: BCL2 inhibitor
Relapsed after 2 or more lines of therapy, including a BCL2 inhibitor
Cannot have received: autologous stem cell transplant
ASCT within 6 weeks of informed consent
Cannot have received: allogeneic hematopoietic stem cell transplantation
History of allogeneic hematopoietic stem cell transplantation
Cannot have received: investigational agent
Less than 28 days elapsed between prior treatment with investigational agent(s) and the day of lymphocyte collection
Lab requirements
Kidney function
calculated creatinine clearance ≥ 30ml/min.
Liver function
total bilirubin ≤ 1.5 x upper institutional limit of normal (except in participants with gilbert's syndrome, active hemolysis or disease involvement of the liver). ast (sgot)/alt ≤ 2.5 x institutional upper limit of normal.
Cardiac function
cardiac ejection fraction of ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute · Cleveland, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06916767 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior autologous stem cell transplant, allogeneic hematopoietic stem cell transplantation, investigational agent disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify